Page 1 of 21Free preview · 1–5

About this document

Vol.:(0123456789)1 3Aging Clinical and Experimental Research (2022) 34:2603 - 2623 https://doi.org/10.1007/s40520-022-02279-6 REVIEW ARTICLE Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group Thierry Chevalley1 · Maria Luisa Brandi2 · Kevin D. Cashman3 · Etienne Cavalier4 · Nicholas C.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

Vol.:(0123456789)1 3Aging Clinical and Experimental Research (2022) 34:2603–2623 https://doi.org/10.1007/s40520-022-02279-6 REVIEW ARTICLE Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group Thierry Chevalley1 · Maria Luisa Brandi2 · Kevin D. Cashman3 · Etienne Cavalier4 · Nicholas C. Harvey5,6 · Stefania Maggi7 · Cyrus Cooper5,6,8 · Nasser Al‑Daghri9 · Oliver Bock10,11 · Olivier Bruyère12 · Mario Miguel Rosa13 · Bernard Cortet14 · Alfonso J. Cruz‑Jentoft15 · Antonio Cherubini16 · Bess Dawson‑Hughes17 · Roger Fielding17 · Nicholas Fuggle5,6 · Philippe Halbout11 · John A. Kanis18,19 · Jean‑Marc Kaufman20 · Olivier Lamy21 · Andrea Laslop22 · Maria Concepción Prieto Yerro23 · Régis Radermecker24 · Jotheeswaran Amuthavalli Thiyagarajan25 · Thierry Thomas26 · Nicola Veronese27 · Marten de Wit28 · Jean‑Yves Reginster29 · René Rizzoli1 Received: 14 September 2022 / Accepted: 10 October 2022 / Published online: 26 October 2022 © The Author(s) 2022 Abstract Vitamin D is a key component for optimal growth and for calcium–phosphate homeostasis. Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age groups. In older adults, recommended doses for vitamin D supplementation vary between 200 and 2000 IU/ day, to achieve a goal of circulating 25-hydroxyvitamin D (calcifediol) of at least 50 nmol/L. The target level depends on the population being supplemented, the assessed system, and the outcome. Several recent large randomized trials with oral vitamin D regimens varying between 2000 and 100,000 IU/month and mostly conducted in vitamin D-replete and healthy individuals have failed to detect any efficacy of these approaches for the prevention of fracture and falls. Considering the well-recognized major musculoskeletal disorders associated with severe vitamin D deficiency and taking into account a possible biphasic effects of vitamin D on fracture and fall risks, an European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group convened, carefully reviewed, and analyzed the meta-analyses of randomized controlled trials on the effects of vitamin D on fracture risk, falls or osteoarthritis, and came to the conclusion that 1000 IU daily should be recommended in patients at increased risk of vitamin D deficiency. The group also addressed the identification of patients possibly benefitting from a vitamin D loading dose to achieve early 25-hydroxyvitamin D therapeutic level or from calcifediol administration. Keywords Vitamin D · Fragility fracture · Falls · Osteoarthritis Introduction Vitamin D plays a major role in optimal growth and in cal- cium–phosphate homeostasis. In humans, skin photosynthe- sis is the main endogenous source of vitamin D. When sun exposure is limited and in case of insufficient vitamin D dietary supply, vitamin D supplementation is recommended particularly in certain age groups [1, 2]. A majority of guide- lines consistently recommend 400 IU/day (10 μg) to prevent rickets during the first year of life [3]. Calcium intake of 200 and 260 mg/day before 6 months and before 12 months, respectively, is also advised [1]. For treatment of nutritional rickets, the dose of 2000 IU/day for at least 3 months is rec- ommended, with a normalization of PTH levels. Whilst rec- ommendations for rickets prevention and treatment in child- hood and adolescence are widely accepted [3], the target for calcifediol (25-hydroxyvitamin D (25(OH)D)) levels is still discordant among the various guidelines [2]. Regarding * Thierry Chevalley Thierry.chevalley@hcuge.ch Extended author information available on the last page of the article

Page 2

2604 Aging Clinical and Experimental Research (2022) 34:2603–26231 3 the preventive effect of vitamin D on fracture, many meta- analyses of RCTs have shown contradictory results, some showing no effect at all, while others showed a beneficial anti-fracture effect of vitamin D supplementation particu- larly when combined with calcium [2, 4]. Although 50 nmol/L of serum of 25(OH)D is considered as a threshold value for optimal bone health by many guide- lines [3], higher concentrations, and correspondingly higher intake of vitamin D, have been suggested by some experts for maintaining bone health [5–8]. However, recent large trials conducted in vitamin D-replete healthy subjects have reported no effects either on falls [9, 10], non-vertebral frac- tures [9, 11], bone health outcomes [10], chronic knee pain [12], various clinical outcomes [13], and body composition [14]. It should be noted that 70% of RCTs with clinical out- comes were performed in patients with baseline 25(OH)D above 40 nmol/L and out of twenty-five large RCTs only one was undertaken in a vitamin D-deficient population (25(OH) D below 25 or 30 nmol/L) and two in vitamin D-insufficient populations (25(OH)D below 50 nmol/L) [15]. Indeed, vita- min D deficiency has been shown to be a risk factor for vari- ous musculoskeletal disorders, including fractures and falls [16, 17]. To identify vitamin D regimens to correct vitamin D deficiency and prevent related musculoskeletal events, a European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group reviewed and analyzed meta-anal- yses of randomized controlled trials on the effects of vitamin D supplementation on fracture risk, falls or osteoarthritis. This paper, which updates the 2013 ESCEO recommenda- tion paper [18], is a narrative review of the data used by the working group to reach the conclusion that 1000 IU vitamin D daily should be recommended in patients at increased risk of vitamin D deficiency. Methods An ESCEO expert working group, comprising expert clini- cians of different medical specialties (physical rehabilitation medicine (PRM) specialists, laboratory medicine special- ists, rheumatologists, endocrinologists and geriatricians) and researchers was convened in May 2022, under the aus- pices of the WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging (University of Liège, Belgium). This group reviewed the literature and discussed the current state of the art on the followings topics: (1) Epi- demiology of vitamin D deficiency; (2) New perspectives in the assessment of vitamin D circulating levels; (3) Vitamin D and fracture prevention (effects in depleted and replete populations); (4) Vitamin D and falls (effects in depleted and replete populations); (5) Vitamin D and osteoarthritis (effects in depleted and replete populations); (6) Metabolic conditions justifying the use of 25(OH)D (calcifediol); and (7) Vitamin D treatment safety and therapeutic window. This paper reflects the presentations and the discussions of the working group based on an extensive narrative literature review focusing on the most robust evidence such as a series of recent meta-analyses. After discussion and deliberation amongst the experts regarding the quality, scope, and con- text of the collected evidence, a first draft of the manuscript was prepared. This draft manuscript was circulated to all the members of the expert group for critical revision. Any addi- tionally identified high-quality evidence was subsequently incorporated. The first author coordinated the preparation of the final version of the manuscript, which was circulated to the entire expert group for final approval and unanimous endorsement. Epidemiology of vitamin D deficiency Vitamin D deficiency varies depending on the thresholds used for serum 25(OH)D values [19]. Furthermore, serum 25(OH)D levels vary over the course of the year in relation to UVB exposure [20–22]. Low thresholds such as 25(OH)D below 25 or 30 nmol/L (i.e., deficiency or severe deficiency, depending on the experts society) have been suggested when the focus was more on the prevention of rickets/osteomalacia and a higher threshold below 50 nmol/L (insufficiency or deficiency, depending on the experts society) was chosen if the concern was suppression of PTH. Using a < 30 nmol/L threshold, 5% of Americans and about 9% of Canadians have serum values of 25(OH)D below this level [22, 23]. Regarding vitamin D status in the United States, an Ameri- can survey between 2011 and 2014 suggested that, on aver- age, 5% of the population was at risk of deficiency as defined with 25(OH)D level below 30 nmol/L, but if the population was divided according to the ethnicity, then the risk of vita- min D deficiency of the Caucasian population was around 2% as compared to 17.5% of the black population [23]. In Europe, 1 out of 8 inhabitants (13% on average) are at risk of vitamin D deficiency (based on a 25(OH)D level below 30 nmol/L), but this percentage can increase up to 28–65% for ethnic minority groups within Northern European coun- tries [24]. However, the prevalence of serum 25(OH)D below 30 nmol/L ranged from 4.6 to 30.7% and this range increased from 27.2 to 61.4% for 25(OH)D using a threshold of 50 nmol/L according to European standardized data [24]. Considering both continents, this represents 120 million of subjects who are vitamin D deficient using a 30 nmol/L threshold and 390 million of subjects with 25(OH)D below 50 nmol/L. Predictors for low 25(OH)D in all models were higher age, higher BMI, use of walking aid, limited time spent outdoors in Summer, smoking, no calcium supplemen- tation, no use of multivitamins, no use of vitamin D on pre- scription or self-administered, and the season when serum

Page 3

2605Aging Clinical and Experimental Research (2022) 34:2603–26231 3 25(OH)D was tested [25]. There are other potential factors that contribute to increased risk of vitamin D deficiency such as inflammation [5, 26, 27], patients with fat malabsorption syndromes, bariatric surgery, nephrotic syndrome, as well as patients on a variety of medications which may interfere with vitamin D absorption or metabolism [5]. The major source of vitamin D in humans is ultravio- let B (UVB)-induced dermal synthesis of cholecalciferol, whereas food sources are believed to play a lesser role, although among white residents of the UK, meat eaters have 20 nmol/L higher 25(OH)D than vegans [28]. There is a clear trend of decreasing UVB exposure by moving from South to North within Europe, with an almost six-fold dif- ference in mean yearly modeled UVB dose between these two latitudes from ~ 35○ to ~ 69○ N [29]. Significant differ- ences in UVB availability between inland and coastal areas were also reported at the same latitude within the UK, due to different cloud conditions [30]. Environmental and per- sonal factors influence cutaneous vitamin D synthesis [31]: the main determinants are solar zenith angle, controlling the potential available UVB (latitude, season and time of day), skin type and age, clothing, sunscreen, and outdoor activities. Therefore, UVB availability and diet, as well as other lifestyle factors, must be considered in preventive and therapeutic approaches to vitamin D deficiency. In Europe, if the extreme North and South are excluded, dietary supply becomes especially important 4–8 months a year when vita- min D synthesis in the skin is very limited and 50–100% of Europeans have vitamin D intakes below the recommended level. Indeed, the vast majority of European countries con- sume below the estimated average requirement of 10 ug/ day of vitamin D intake (400 IU) based on European dietary surveys with a mean intake of 3.3 and 2.7 ug/day in adult males and females, respectively [32]. The mean vitamin D intake varies between 1.5 and 5 μg/day in Western Europe and below 1 μg/day to about 3 μg/day in Southern Europe, while in Northern Europe it ranges between 4 and 14 μg/ day [33]. According to WHO, the strategies for the control of micronutrient malnutrition are to increase the diversity of the foods consumed, food fortification and supplemen- tation [34]. Nevertheless, increasing the diversity of foods consumed and improving intake of naturally occurring vita- min D-rich foods is particularly challenging because there are very few food sources rich in vitamin D. For a serum 25(OH)D threshold of 25 nmol/L, a vitamin D intake range of 7.5 and 10 μg/day would allow 95% and 97.5% of individ- uals, respectively, to maintain their winter serum 25(OH)D above this threshold. On the other hand, for a serum 25(OH) D threshold of 50 nmol/L, the corresponding vitamin D intakes needed are 23.5 and 25 ug/day (≈ 1000 IU/day), respectively, intakes which are too difficult to reach with food fortification and may need a more active public health approach involving recommendations for lifestyle including sunshine exposure, healthy nutrition, food fortification, and vitamin D supplementation [35]. In summary, vitamin D deficiency (25(OH)D below 25 or 30 nmol/L) is evident throughout the European population at prevalence rates that are of concern and that require action both from a public health and a clinical perspective. New perspectives in the assessment of vitamin D circulating levels Commonly cited indications where vitamin D testing is appropriate are: rickets, osteomalacia, osteoporosis, hyper- parathyroidism, malabsorption syndromes, medications affecting absorption or metabolism of vitamin D (anti- fungals, HIV antiretroviral therapy, anticonvulsants, etc.), chronic kidney disease, hypophosphatemia and hypo/hyper- calcemia, deeply pigmented skin, and isolated elevation of alkaline phosphatase [36]. A major issue in the determina- tion of a 25(OH)D threshold value is the absolute need for a standardized method. In 2010, the Vitamin D External Quality Assessment Scheme (DEQAS) for the determination of 25(OH)D included 13 different methods which displayed high coefficient of variation and a range of fourfold between the lowest and highest values for a given sample. To stand- ardize 25(OH)D measurement in both clinical and research laboratories, the Vitamin D Standardization Program (VDSP) was agreed in 2010 by the Office of Dietary Supple- ments (ODS) of the National Institutes of Health (NIH) [37]. This collaboration involved the coordinated efforts of ODS, the National Institute for Standards and Technology (NIST), the Centers for Disease Control and Prevention (CDC), the Vitamin D External Quality Assessment Scheme (DEQAS), the College of American Pathologists (CAP), the Ameri- can Association for Clinical Chemistry (AACC), the Inter- national Federation of Clinical Chemistry and Laboratory Medicine (IFCC), along with national surveys and collabora- tors around the world. The VDSCP calibration-certification process conducted by CDC comprised 2 phases: Phase 1 assessed and readjusted current calibration based on 40 sin- gle donor samples with assigned target values. In Phase 2, four quarterly challenges with 10 unknown serum samples were performed to verify that calibration was stable over 1 year. If performance criteria of a mean bias ≤ ± 5% and an imprecision ≤ 10% were reached, then the certified labs were listed on the CDC website https://www.cdc.gov/labstandar ds/pdf/hs/CDC_Certified_Vitamin_D_Procedures-508.pdf. In 2018, the DEQAS reported an explosion of the number of methods for 25(OH)D determination, but with lower coef- ficient of variation values as compared to 2010 and a nar- rowing distribution with a smaller range of twofold between the lowest and highest values for a given sample. The impact of the VDSP re-standardization was an overall improvement in the bias observed between the reference method and the

Page 4

2606 Aging Clinical and Experimental Research (2022) 34:2603–26231 3 different commercially available assays. Liquid chromatog- raphy–mass spectrometry (LCMS/MS) methods performed globally better than immunoassays, but all LCMS/MS meth- ods are not equivalent and there are still important issues with immunoassays and LCMS/MS. All the standardization process was performed with sam- ples from healthy individuals, but 25(OH)D should also be measured in patients with different diseases (CKD, osteo- porosis, etc.), physiological status (pregnancy), or ethnicity. Vitamin D binding protein concentration and polymorphism have also an impact on the results. In addition serum matrix may be different in sick patients and in healthy individuals [38]. The vitamin D metabolite ratio (VMR) 24,25(OH)2D to 25(OH)D has been proposed as a new marker of vitamin D status and as being predictive of fracture risk [39]. Cavalier et al. suggested that in clinical practice the concentrations of 24,25(OH)2D and 25(OH)D should be reported together with the probability that a ratio value is found in healthy subjects [40]. This information would allow one to escape the concept of vitamin D deficiency solely on the basis of a 25(OH)D threshold [5, 41–43]. For example, amongst indi- viduals with a 25(OH)D concentration above 52 nmol/L, over 99% exhibit detectable amounts of 24,25(OH)2D and, thus, are probably vitamin D sufficient [44]. This finding supports the 50 nmol/L cut-off recommended by the IOF [45]. However, the ratio 24,25(OH)2D to 25(OH)D can only be measured after determination of both moieties by LCMS/ MS. In summary, great improvements in 25(OH)D assays standardization have been achieved in recent years. LCMS/ MS methods generally perform better than immunoassays, but all LCMS/MS methods are not equivalent. 24,25(OH)2D and VMR are promising tools to evaluate vitamin D defi- ciency at the individual level, but are only available with LCMS/MS. Vitamin D and fracture risk In a prospective observational study in 1662 community- dwelling elderly men followed over a period of 4 years, a U-shaped association was observed with an increased risk of fracture in men with either 25(OH)D values below 36 nmol/L or above 75 nmol/L [46]. Whether vitamin D, calcium or both supplements together are effective for the primary prevention of fractures is still debated. The absence or the demonstration of a beneficial anti-fracture effect is linked not only to the vitamin D dose, addition or not of calcium and duration of vitamin D supplementation but also largely to the population studied and in particular if this population is vitamin D deplete or replete. In a Cochrane review [47], taking into account 11 studies involving more than 27,000 patients, vitamin D alone did not prevent hip fractures or any fractures (the latter based on 15 studies including more than 28,000 patients) (Table 1). On the other hand, the combination of vitamin D and cal- cium reduced the incidence of hip fractures by 16% based on 9 studies in almost 50,000 patients and the risk of any fractures by 5% taking into account 10 studies involving nearly 50,000 patients. In addition, fracture risk reduction was shown to be more important in institutionalized patients both for hip and for any fractures [47]. Nevertheless, even in institutionalized patients, the reduction of fracture inci- dence seems to be dependent on baseline serum 25(OH) D levels. Indeed, in 3,270 French institutionalized women with a mean age of 85 years and a baseline serum 25(OH) D of 35 nmol/L, a supplementation of 800 IU of vitamin D and 1200 mg of calcium for 18 months reduced the inci- dence of hip and of non-vertebral fractures [48]. In contrast, in an English study among 3440 institutionalized men and women with a mean age of 85 years, but with a baseline 25(OH)D above 54 nmol/L, a supplementation of 100,000 units of vitamin D every 4 months for 3 years did not show a significant decrease in the incidence of fractures at the hip or at other sites [49]. More recently the Do-Health study involving 2157 elderly subjects with a baseline 25(OH) D of 56 nmol/L, a daily supplementation of 2000 IU of vitamin D for 3 years did not reduce the incidence of non- vertebral fractures [13]. In the VITAL trial performed in more than 25,000 vitamin D-replete subjects, there was no anti-fracture effect of 2000 IU/day of vitamin D [11]. With only 7 against 8 fractures in patients with 25(OH)D below a not prespecified 30 nmol/L threshold, a conclusion as to whether a response to supplementation is detectable in vita- min D-deficient patients cannot be drawn. In the ViDA trial in New Zealand, a monthly administra- tion of 100,000 IU of vitamin D over about 3 years, after a loading dose of 200,000 IU, did not prevent fractures with even a non-significant trend for a higher fracture risk observed among healthy volunteers aged between 50 and 84 years and with a baseline 25(OH)D of 63 nmol/L [9]. Furthermore, an increase in falls and fractures was also pre- viously observed with an annual high bolus of 500,000 IU of vitamin D in community-dwelling elderly Australian women at high risk of fracture, but with a baseline 25(OH)D consid- ered as sufficient at around 50 nmol/L [50]. Many meta-analyses including various numbers of tri- als, hence of subjects, were recently published [47, 51–66] (Table 1). In that of Bolland et al. [59], which included 81 studies but with only 6% of vitamin D-deficient subjects at baseline, supplementation of vitamin D alone was not associated with a reduction of the incidence of total and hip fractures as well as of falls. Moreover this system- atic review not only excluded trials combining vitamin D and calcium but included studies either with low doses of vitamin D or conversely high doses, especially bolus,

Page 5

2607Aging Clinical and Experimental Research (2022) 34:2603–26231 3 Table 1 Meta-analyses on vitamin D supplementation and fractures Author, year, studies Intervention tested Target population and limitations Results for fractures Bischoff-Ferrari et al. (2009) [51] 12 RCTs (non- vertebral fractures) N = 42,279 8 RCTs (hip fractures) N = 40,886 Vit D ± calcium Vit D ≤ 400 IU/d in 3 trials whereas the other 9 RCTs had mean intakes of 482–770 IU/d Mean age of 78 years, 89% women Duration from 12 to 84 months Pooled relative risk 0.86 (95% CI 0.77–0.96) for prevention of non-vertebral fracture and 0.91 (95% CI 0.78–1.05) for hip fracture Calcium 500–1200 mg/d in combination with vit D in 7 RCTs For the higher dose (> 400 IU), pooled RR 0.80 (95% CI 0.72–0.89); n = 33,265, 9 trials for non-vertebral fractures and 0.82 (95% CI 0.69– 0.97); n = 31,872, 5 trials for hip fractures Lai et al. (2010) [52] 7 RCTs N = 12,762 Vit D alone 400–1100 IU/day in 6 RCTs Vit D 800 IU + calcium 1000 mg/day in 1 RCT RCT including a minimum of 100 participants with at least one radiologically confirmed hip fracture in each group RR 1.13 (95% CI 0.98–1.29) for hip fractures No significant variations found between results of studies randomizing participants to: < 800 IU/day 1.14 (95% CI 0.86–1.49) or ≥ 800 IU/day 1.12 (95% CI 0.96–1.32) Bergman et al. (2010) [53] 8 RCTs N = 12,658 Vit D ± calcium 4 RCTs on non-vertebral fracture, n = 3510 5 RCTs on hip fracture, n = 7473 Vit D3 + calcium compared to placebo: OR 0.77 (95% CI 0.6–0.93) for non-vertebral fracture and OR 0.70 (95% CI 0.53–0.90) for hip fracture Chung et al. (2011) [54] 16 RCTs N = 19,878 Vit D (400–1370 IU/d) alone 5 RCTs—N = 14,583 Elderly men and women with follow-up ranging from 7 months to 5 years Pooled relative risk 1.03 [95% CI 0.84 to 1.26], with high heterogeneity Vit D (300–1000 IU/d) + calcium 500– 1200 mg/d 11 RCTs—N = 52,915 Pooled relative risk, 0.88 [95% CI 0.78–0.99], with moderate heterogeneity Significant risk reduction among institutional- ized elderly persons (relative risk, 0.71 [95% CI 0.57–0.89]) Murad et al. (2012) [55] Network meta-analysis Vit D ± calcium Median age, 64 years; 86% females and 88% Caucasians; median follow-up, 24 months OR 0.81 (95% CI 0.68–0.96) for hip fracture and OR 0.94 (95% CI 0.84–1.02) for non-vertebral fracture Vit D and calcium given separately were ineffective Avenell et al. (2014) [47] 31 RCTs N = 36,282 Vit D alone 11 RCTs, N = 27 693 15 RCTs, N = 28 272 12/31 RCTs had participants with a mean or median age of 80 years or over RR 1.12 (95% CI 0.98–1.29) for hip fracture RR 1.03 (95% CI 0.96–1.11) for any fracture Vit D + calcium 9 RCTs, N = 49 853 10 RCTs, N = 49 976 Institutional (2 RCTs), N = 3853 Prevention of fractures in community, nursing home or hospital inpatient populations RR 0.84 (95% CI 0.74–0.96) for hip fracture RR 0.95 (95% CI 0.90–0.99) for any fracture RR 0.75 (95% CI 0.62, 0.92) and RR 0.85 (95% CI 0.74, 0.98) for hip and any fracture, respectively in institutionalized-dwellingsubjects Weaver et al. (2016) [56] 8 RCTs N = 30,970 Vit D + calcium Mostly adults aged 65 + years – Excluded studies that tested vit D without calcium – Included 40% of the literature that contributed to current guidelines on vit D 15% reduction of total fractures (RR = 0.85; 95% CI 0.73–0.98) 30% reduction of hip fractures (RR = 0.70; 95% CI 0.56–0.87)

Doxxly editorial guide

Role of vitamin D supplementation in the management: summary, contents and background

This guide helps you understand the scope of Role of vitamin D supplementation in the management before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

Role of vitamin D supplementation in the management is a 21-page documentcredited to Orson M. Dunmore. Vol.:(0123456789)1 3Aging Clinical and Experimental Research (2022) 34:2603 - 2623 https://doi.org/10.1007/s40520-022-02279-6 REVIEW ARTICLE Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group Thierry Chevalley1 · Maria Luisa Brandi2 · Kevin D. Cashman3 · Etienne Cavalier4 · Nicholas C.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of its central subject with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with its central subject. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 21 pages in the player.

  1. Part 1

    background

    Use this section of the reading guide to identify how background appears in Role of vitamin D supplementation in the management, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    key ideas

    Use this section of the reading guide to identify how key ideas appears in Role of vitamin D supplementation in the management, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    practical context

    Use this section of the reading guide to identify how practical context appears in Role of vitamin D supplementation in the management, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Orson M. Dunmore

Doxxly credits Orson M. Dunmore as the author or creator of Role of vitamin D supplementation in the management. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is esceo.org. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit esceo.org

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read Role of vitamin D supplementation in the management, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the related collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Frequently asked questions about Role of vitamin D supplementation in the management

Practical answers about reading, downloading and understanding this document on Doxxly.